GLP-1semaglutideliraglutideantipsychoticsmetabolic syndromemeta-analysis

Meta-analysis finds GLP-1 agonists cut 6.5 kg in antipsychotic-treated patients

Eight randomized trials with 535 participants showed reductions in BMI, HbA1c, waist circumference and visceral fat, with higher rates of nausea, vomiting and constipation.

By Maren Holt · Senior Reporter, GLP-1

Oct 23 20:00 ETSource: European journal of clinical pharmacology

The wire

01Pooled results across eight RCTs showed body weight down 6.54 kg, BMI down 2.34 kg/m2, HbA1c down 0.32% and waist circumference down 5.22 cm with GLP-1 receptor agonists in adults on antipsychotics.
02Weight reduction was greatest with semaglutide, then liraglutide, and increased with longer treatment duration, giving prescribers subgroup signals for patients with severe mental illness.
03Heterogeneity was high for weight and BMI (I2 92% and 85%), the total sample was only 535 randomized participants, and no significant effects were seen for total cholesterol, triglycerides or HDL-C.

From the source

Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis
European journal of clinical pharmacology · 2026 Oct 24 · Zhou L, Zhang Y, Shen C et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42920001/